Quadrature Capital Ltd Makes New Investment in Cardlytics, Inc. (NASDAQ:CDLX)

Quadrature Capital Ltd purchased a new position in Cardlytics, Inc. (NASDAQ:CDLX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,652 shares of the company’s stock, valued at approximately $63,000.

Other hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Cardlytics by 6.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock valued at $432,000 after acquiring an additional 1,774 shares during the period. Canton Hathaway LLC increased its position in shares of Cardlytics by 95.7% in the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares during the period. Bank of New York Mellon Corp increased its position in shares of Cardlytics by 15.4% in the second quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after acquiring an additional 18,179 shares during the period. Ingalls & Snyder LLC increased its position in shares of Cardlytics by 106.0% in the second quarter. Ingalls & Snyder LLC now owns 32,464 shares of the company’s stock valued at $267,000 after acquiring an additional 16,708 shares during the period. Finally, Quest Partners LLC increased its position in shares of Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after buying an additional 11,061 shares during the period. 68.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

CDLX has been the topic of several research analyst reports. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI initiated coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target on the stock. Northland Capmk cut shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Finally, Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.92.

Cardlytics Price Performance

Shares of CDLX opened at $3.58 on Friday. The firm’s 50-day simple moving average is $3.89 and its two-hundred day simple moving average is $5.48. The stock has a market cap of $181.94 million, a PE ratio of -0.59 and a beta of 1.53. Cardlytics, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The company had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. The firm’s revenue for the quarter was down 15.1% compared to the same quarter last year. Analysts anticipate that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

Insider Transactions at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alexis Desieno sold 25,118 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74. Following the transaction, the chief financial officer now owns 116,481 shares of the company’s stock, valued at $399,529.83. This trade represents a 17.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,691 shares of company stock valued at $237,767 over the last three months. Corporate insiders own 4.40% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.